切换至 "中华医学电子期刊资源库"
高级检索
中华卫生应急电子杂志

中华卫生应急电子杂志 ›› 2018, Vol. 04 ›› Issue (05) : 264 -272. doi: 10.3877/cma.j.issn.2095-9133.2018.05.002

所属专题： 文献；

论著

一种促进神经损伤修复的药物组合物治疗22例ALS患者1年后的疗效观察
岳茂兴1,†(), 周培根2, 郝冬琳2, 李瑛2, 尹进南2, 郑琦涵2, 杨学峰2, 梅冰3, 孙志辉3, 马临庆3, 徐冰心4, 吴静2, 吴娟2, 郁婷婷2, 钱亿超2, 朱晓瓞2, 冯斌2, 徐君晨2, 关竹颖2, 岳慧2, 魏艳红3   
  1. 1. 213017　江苏常州，江苏大学附属武进医院；100101　北京，中国人民解放军第三○六医院
    2. 213017　江苏常州，江苏大学附属武进医院
    3. 215219　江苏苏州，苏州高新区人民医院
    4. 100101　北京，中国人民解放军第三○六医院
  • 收稿日期:2018-09-02 出版日期:2018-10-18
  • 通信作者: 岳茂兴
  • 基金资助:
    国家重点实验室开放课题(SKLKF201601); 常州市2016年度应用基础研究项目(CJ20160006); 常州市武进区2016年度社会发展项目(WS201608)

Therapeutic effect of a pharmaceutical composition on promoting nerve repair in amyotrophic lateral sclerosis: report of twenty-two cases with follow-up for one year

Maoxing Yue1,†(), Peigen Zhou2, Donglin Hao2, Ying Li2, Jinnan Yin2, Qihan Zheng2, Xuefeng Yang2, Bing Mei3, Zhihui Sun3, Linqing Ma3, Bingxin Xu4, Jing Wu2, Juan Wu2, Tingting Yu2, Yichao Qian2, Xiaodie Zhu2, Bin Feng2, Junchen Xu2, Zhuying Guan2, Hui Yue2, Yanhong Wei3   

  1. 1. Affiliated Wujin Hospital of Jiangsu University, Changzhou 213017, China; 306 Hospital of PLA, Beijing 100101, China
    2. Affiliated Wujin Hospital of Jiangsu University, Changzhou 213017, China
    3. The People’s Hospital of SND, Suzhou 215219, China
    4. 306 Hospital of PLA, Beijing 100101, China
  • Received:2018-09-02 Published:2018-10-18
  • Corresponding author: Maoxing Yue
  • About author:
    Corresponding author: Yue Maoxing, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

岳茂兴, 周培根, 郝冬琳, 李瑛, 尹进南, 郑琦涵, 杨学峰, 梅冰, 孙志辉, 马临庆, 徐冰心, 吴静, 吴娟, 郁婷婷, 钱亿超, 朱晓瓞, 冯斌, 徐君晨, 关竹颖, 岳慧, 魏艳红. 一种促进神经损伤修复的药物组合物治疗22例ALS患者1年后的疗效观察[J]. 中华卫生应急电子杂志, 2018, 04(05): 264-272.

Maoxing Yue, Peigen Zhou, Donglin Hao, Ying Li, Jinnan Yin, Qihan Zheng, Xuefeng Yang, Bing Mei, Zhihui Sun, Linqing Ma, Bingxin Xu, Jing Wu, Juan Wu, Tingting Yu, Yichao Qian, Xiaodie Zhu, Bin Feng, Junchen Xu, Zhuying Guan, Hui Yue, Yanhong Wei. Therapeutic effect of a pharmaceutical composition on promoting nerve repair in amyotrophic lateral sclerosis: report of twenty-two cases with follow-up for one year[J]. Chinese Journal of Hygiene Rescue(Electronic Edition), 2018, 04(05): 264-272.

目的

观察一种促进神经损伤修复的药物组合物治疗肌萎缩侧索硬化症(ALS)患者的疗效。

方法

选取2015年4月至2017年9月江苏大学附属武进医院及苏州高新区人民医院收治的22例ALS患者为研究对象进行前瞻性自身对照研究，其中男性10例，女性12例；年龄34～68岁，平均年龄(51.64 ± 9.28)岁。在常规综合治疗基础上，将一种促进神经损伤修复的药物组合物[精氨酸1.5～5 g，异亮氨酸1.5～5 g，亮氨酸2.5～7.5 g，赖氨酸1.5～5 g，蛋氨酸0.25～1.5 g，苯丙氨酸0.25～1.5 g，苏氨酸1.5～5 g，色氨酸0.25～1.5 g，缬氨酸2.5～7.5 g，组氨酸1.5～4 g，甘氨酸1.5～4 g，丙氨酸1.5～5 g，脯氨酸1.5～4 g，天冬酰胺0.05～1.5 g，半胱氨酸0.05～1.5 g，谷氨酸1.5～5 g，丝氨酸0.25～2.5 g，酪氨酸0.05～1.5 g，L～鸟氨酸0.25～4 g，天冬氨酸0.5～2.5 g；维生素(维生素B1 1～2 mg，维生素B2 1～2 mg，维生素B6 3～10 g，维生素C 1～3 g)]配制在1个三升输液袋内进行静脉输注，1次/d，28 d为1个疗程，休息2周后行第2个疗程，持续治疗时间≥4个疗程或6个月。观察患者治疗前后及随访的国际肌萎缩侧索硬化症改良功能评分量表(ALSFRS-R)评分、疾病进展率及症状体征等变化情况。

结果

本组22例ALS患者中死亡1例(4.55%)，为疾病晚期呼吸衰竭。肌肉萎缩好转、肌力增加3例(13.6%)，舌肌萎缩、构音障碍好转1例(4.5%)，流涎好转2例(9.1%)，吞咽功能改善1例(4.5%)，四肢活动度增加2例(9.1%)，1例(4.5%)不能站立和行走的患者可搀扶站立。各阶段ALSFRS-R评分波动范围：首次门诊时为18.0～44.0分，治疗6个月时为18.0～41.0分，末次治疗时为12.0～39.0分之间，末次随访时为6.0～38.0分。治疗6个月时ALSFRS-R评分与治疗前比较，差异无统计学意义[24.50(12.3)分比27.15(14.7)分，Z＝-1.183，P>0.05]，6例(27.3%)患者的ALSFRS-R评分上升，4例(18.2%)评分不变，12例(54.5%)评分下降。末次治疗时ALSFRS-R评分与治疗前相比有所下降[23.50(6.0)分比27.15(14.7)分，Z＝－2.557，P>0.05]，但仍有6例(27.3%)患者的评分上升。治疗6个月和末次治疗时的疾病进展率虽与治疗前的差异无统计学意义[0.521(0.563)分/月比0.673(0.716)分/月，Z＝－1.834；(0.702±0.469)分/月比(0.716±0.440)分/月，t＝0.259。P均>0.05]，但仍分别有72.7%(16/22)和54.5%(12/22)的患者疾病进展率较前下降。对所有患者随访至首次治疗后1年以上发现，其ALSFR-R评分4例(18.2%)上升，1例(4.5%)不变，17例(77.3%)下降，且疾病进展率低于治疗前[(0.584±0.372)分/月比(0.716±0.440)分/月，t＝2.706，P<0.05]。经过长期规范化治疗的患者，即使停止用药一段时间，仍然有72.7%(16/22)患者的疾病进展速率得以减缓。

结论

该促进神经损伤修复的药物组合物能在整体上为ALS患者提供机体新陈代谢的底物、辅酶与强劲的动能，通过促进机体酶与氨基酸代谢以及血液循环，使受损、变性的神经系统功能得到一定程度的修复，增强了神经元的存活能力，从而延缓疾病发展，改善病情与临床症状。新疗法的确无毒无害无副作用，重复性好。

关键词: 肌萎缩侧索硬化症, 疗效, 神经损伤修复, 药物组合物
Objective

To observe the efficacy of a pharmaceutical composition for promoting nerve repair in patients with amyotrophic lateral sclerosis (ALS).

Methods

Twenty-two patients with ALS admitted to Affiliated Wujin Hospital of Jiangsu University and the People's Hospital of SND from April 2015 to September 2017 were enrolled in this study. The prospective self-controlled study included 10 males and 12 females, aged 34 to 68 years, with average age (51.64±9.28) years. On the basis of conventional comprehensive treatment, the pharmaceutical composition [The main components: arginine 1.5-5 g, isoleucine 1.5-5 g, lysine 2.5-7.5 g, methionine 0.5-1.5 g, phenylalanine 0.5-5 g, tryptophan 0.5-1.5 g, valine 2.5-7.5 g, histidine 1.5-4 g, glycine 1.5-4 g, alanine 1.5-5 g, proline 1.5-4 g, asparagine 0.05-1.5 g, cysteine 0.05-1.5 g, cysteine 1.5-5 g, serine 0.25-2.5 g, Tyrosine 0.05-1.5 g, L-ornithine 0.25-4 g, aspartic acid 0.5-2.5 g. Vitamins (vitamin B1 1-2 mg, vitamin B2 1-2 mg, vitamin B6 3-10 g, vitamin C 1-3 g)] were prepared in a three-liter infusion bag for intravenous infusion, once a day for 28 days for a course of treatment, the next course should be followed after a drug withdrawal for 2 weeks, and the continuous treatment lasted at least for 4 courses or 6 months. The changes of the amyotrophic lateral sclerosis modified functional rating scale-revised (ALSFRS-R), disease progression rate and symptoms and signs were observed in all patients pre- and post-treatment.

Results

One of the 22 patients with ALS (4.55%) died from the advanced respiratory failure in the terminal phase of disease. Symptoms of muscle atrophy and muscle strength were improved in 3 cases (13.6%). Symptoms of atrophy of tongue muscle and dysarthria were improved in 1 case (4.5%). Symptoms of salivation were improved in 2 cases (9.1%). Swallowing function were improved in 1 case (4.5%). Limb activity were increased in 2 cases (9.1%). 1 patient (4.5%) who could not stand and walk restored the standing ability (under other’s support) after treatment. The fluctuation ranges of ALSFRS-R scores in each stage were 18.0~44.0 points for the first outpatient visit, 18.0~41.0 points for the 6 months of treatment, 12.0~39.0 points for the last treatment, and 6.0~38.0 points for the last follow-up. After 6 months of treatment, the ALSFRS-R score was not significantly different from that before treatment [24.50(12.3) points vs. 27.15(14.7)points, Z =-1.183, P>0.05], while 6 patients (27.3%) had an increased ALSFRS-R score, 4 patients (18.2%) remained the same, and 12 patients (54.5%) had a lower one. The ALSFRS-R score after the last treatment decreased compared with that before treatment [23.50 (6.0) points vs.27.15 (14.7) points, Z=-2.557, P>0.05]; however, 6 cases (27.3%) still had an increased score. Although the disease progression rate at neither 6 months of treatment nor the last treatment was statistically different from that before treatment [0.521 (0.563) points/month vs. 0.673 (0.716) points/month, Z=-1.834, P>0.05], they still got a lower rate of disease progression in 72.7% (16/22) and 54.5% (12/22) patients. All patients were followed up to more than 1 year since the first treatment, and the ALSFR-R score increased in 4 (18.2%), 1 (4.5%) remained unchanged, and 17 (77.3%) decreased, but the progression rate of the decline was still slower as compared with those before treatment [(0.584±0.372) points/month vs. (0.716±0.440) points/month, t = 2.706, P<0.05]. The last follow-up showed that 72.7% (16/22) of patients who had undergone a long-term standardized treatment still had a slower rate of disease progression even if they stopped the drug delivery for a while.

Conclusions

This pharmaceutical composition for promoting nerve repair can provide the ALS patients with metabolic substrate, coenzyme and energy as a whole, make the damage and degeneration of the nervous system repaired in a certain extent by promoting enzyme and amino acid metabolism and blood circulation, enhance the survival of neurons, to result in delaying the development of the disease and improving the condition and clinical symptoms. The new treatment is indeed non-toxic, harmless and reproducible with no side effects.

Key words: Amyotrophic lateral sclerosis, Curative effect, Repair of nerve Injuries, Pharmaceutical composition
图1 22例ALS患者治疗治疗6个月前后的ALSFRS-R评分变化
图2 22例ALS患者治疗末次治疗前后的ALSFRS-R评分变化
图3 22例ALS患者治疗末次随访(距首次用药后的时间≥12月)前后的ALSFRS-R评分变化
表1 22例ALS患者治疗及随访后疾病进展率变化[例，n(%)]
时间 例数 升高 降低
治疗6个月 22 6(27.3) 16(72.7)
末次治疗 22 10(45.5) 12(54.5)
末次随访 22 6(27.3) 16(72.7)
1
Es MAV，Hardiman O，Chio A，et al.Amyotrophic lateral sclerosis[J]．Lancet，2017，390(10107):2084-2098.
2
Nonneman A，Criem N，Lewandowski SA，et al.Astrocyte-derived Jagged-1 mitigates deleterious Notch signaling in amyotrophic lateral sclerosis[J]．Neurobiol Dis，2018(119): 26-40.
3
Mathis S，Couratier P，Julian A，et al.Current view and perspectives in amyotrophic lateral sclerosis[J]．Neural Regen Res，2017，12(2):181-184.
4
Peters OM，Lewis EA，Osterloh JM，et al.Loss of Sarm1 does not suppress motor neuron degeneration in the SOD1G93A mouse model of amyotrophic lateralsclerosis[J]．Hum Mol Genet，2018，27 (21):3761-3771.
5
Nabavi SM，Arab L，Jarooghi N，et al.Safety，feasibility of intravenous and intrathecal injection of autologous bone marrow derived mesenchymal stromal cells in patients with amyotrophic lateral sclerosis: an open label phase i clinical trial[J]．Cell J，2018，20(4):592-598.
6
Huisman MH，de Jong SW，van Doormaal PTC，et al.Population based epidemiology of amyotrophic lateral sclerosis using capture-recapture methodology[J]．J Neurol Neurosurg Psychiatr，2011，82(10):1165-1170.
7
Logroscino G，Traynor BJ，Hardiman O，et al.Incidence of amyotrophic lateral sclerosis in Europe[J]．J Neurol Neurosurg Psychiatry，2010，81(4):385-390.
8
中华医学会神经病学分会肌电图与临床神经电生理学组．中国肌萎缩侧索硬化诊断和治疗指南[J]．中华神经科杂志，2012，45(7):531-533.
9
陈璐，樊东升．肌萎缩侧索硬化症的自然病史和临床特征[J]．中华内科杂志，2014，53(9):752-754.
10
World Federation of Neurology Research Group on Neuromuscular Diseases.El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis[J]．J Neurol Sci，1994，124(Suppl):96-107.
11
Brooks BR，Miller RG，Swash M，et al.El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis[J]．Amyotroph Lateral Scler Other Motor Neuron Disord，2000，1(5):293-299.
12
de Carvalho M，Dengler R，Eisen A，et al.Electrodiagnostic criteria for diagnosis of ALS[J]．Clin Neurophysiol，2008，119(3):497-503.
13
中华医学会神经病学分会．肌萎缩侧索硬化的诊断标准(草案)[J]．中华神经科杂志，2001，34(3):190.
14
Cedarbaum JM，Stambler N，Malta E，et al.The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III)[J]．J Neurol Sci，1999，169(1-2):13-21.
15
Lee M，McCambridge A．Clinimetrics：amyotrophic lateral sclerosis functional rating scale-revised (ALSFRS-R)[J]．J Physiother，2018，64 (4):269-270.
16
Chiò A，Mora G，Leone M，et al.Early symptom progression rate is related to ALS outcome：a prospective population based study[J]．Neurology，2002，59(1):99-103.
17
Gomeni R，Fava M．Amyotrophic lateral sclerosis disease progression model[J]．Amyotroph Lateral Scler Frontotemporal Degener，2014，15(1-2):119-129.
18
Gordon PH，Cheung YK.Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS[J]．Neurology，2006，66(7):1314-1315.
19
Proudfoot M，Jones A，Talbot K，et al.The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset[J]．Amyotroph Lateral Scler Frontotemporal Degener，2016，17(5-6):414-425.
20
康丽，胡芳芳，靳娇婷，等．肌萎缩侧索硬化症患者生存期的影响因素分析[J]．西安交通大学学报(医学版)，2018，39(5):639-643.
21
郑勇，臧大维．肌萎缩性侧索硬化患者粒细胞集落刺激因子的水平[J]．广东医学，2017，38(18):2806-2809.
22
Robberecht W，Philips T．The changing scene of amyotrophic lateral sclerosis[J]．Nat Rev Neurosci，2013，14(4):248-264.
23
周丽娜，宋春莉．肌萎缩侧索硬化基因研究进展[J]．医学与哲学(B)，2017，38(9): 61-64.
24
Renton AE，Chiò A，Traynor BJ.State of play in amyotrophic lateral sclerosis genetics[J]．Nat Neurosci，2014，17(1):17-23.
25
Williams KL，Topp S，Shu Y，et al.CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia[J]．Nat Commun，2016，7(11253):11253.
26
Wagner ML，Landis BE.Riluzole: a new agent for amyotrophic lateral sclerosis[J]．Ann Pharmacother，1997，31(6):738-744.
27
Miller RG，Mitchell JD，Lyon M，et al.Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)[J]．Amyotroph Lateral Scler Other Motor Neuron Disord，2003，4(3):191-206.
28
Vucic S，Lin CS，Cheah BC，et al.Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis[J]．Brain，2013，136(Pt 5):1361-1370.
29
Dash RP，Babu RJ，Srinivas NR.Two decades-long journey from riluzole to edaravone: revisiting the clinical pharmacokinetics of the only two amyotrophic lateral sclerosis therapeutics[J]．Clin Pharmacokinet，2018，57(11):1385-1398.
30
Okada M，Yamashita S，Ueyama H，et al.Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis[J]．eNeurologicalSc，2018，11:11-14.
31
Wang Y，Liu Y，Zhai J，et al.scAAV9-VEGF-165 inhibits neuroinflammatory response and invasion of macrophages into the peripheral nervous system of ALS transgenic mice[J]．Brain Res Bull，2018，140:233-242.
32
Zhong SJ，Gong YH，Lin YC.Combined intranasal nerve growth factor and ventricle neural stem cell grafts prolong survival and improve disease outcome in amyotrophic lateral sclerosis transgenic mice[J]．Neurosci Lett，2017，656:1-8.
33
Rauskolb S，Dombert B，Sendtner M．Insulin-like growth factor 1 in diabetic neuropathy and amyotrophic lateral sclerosis[J]．Neurobiol Dis，2016，97(Pt B):103-113.
34
Harandi VM，Lindquist S，Kolan SS，et al.Analysis of neurotrophic factors in limb and extraocular muscles of mouse model of amyotrophic lateral sclerosis[J]．Plos One，2014，9(10):e109833.
35
Nagara Y，Tateishi T，Yamasaki R，et al.Impaired cytoplasmic-nuclear transport of hypoxia-inducible factor-1α in amyotrophic lateral sclerosis[J]．Brain Pathol，2013，23(5):534-546.
36
Baloh RH，Glass JD，Svendsen CN.Stem cell transplantation for amyotrophic lateral sclerosis[J]．Curr Opin Neurol，2018，31(5):655-661.
37
邓敏，樊东升．干细胞治疗肌萎缩侧索硬化的研究进展[J]．中国实用内科杂志，2007，27(10):745-748.
38
侯书敏，张江涛．肌萎缩侧索硬化干细胞治疗研究进展[J]．临床和实验医学杂志，2014，13(16):1390-1392.
39
夏增飞，薛杏．干细胞治疗肌萎缩侧索硬化症的最新研究进展[J]．中风与神经疾病杂志，2017，34(8):752-755.
40
李娜，詹青．肌萎缩侧索硬化中医药研究进展[J]．神经病学与神经康复学杂志，2018，14(1): 38-41.
41
张印生，韩学杰．孙思邈医学全书[M]．北京：中国中医药出版社，2009：1-1021.
42
黄诒森．生物化学[M]．第3版．北京：人民卫生出版社，1994：125.
43
谢海，王世文，曹宏霞，等．大剂量γ-氨基丁酸与二巯基丙磺酸钠联合维生素B6对毒鼠强中毒大鼠的解毒作用[J]．中华急诊医学杂志，2010，19(7):703-707.
44
Martin DL，Rimvall K．Regulation of γ-aminobutyric acid synthesis in the brain[J]．J Neurochem，1993，60(2):395-407.
45
GJB 7141-2011液体推进剂损伤诊断标准及处理原则[S]．北京：中国人民解放军总后勤部，2011.
46
中国人民解放军总后勤部卫生部．战伤救治规则[S]．北京：中国人民解放军总后勤部卫生部，2006：94-95.
[1] 张华, 孙宇, 乡世健, 李樱媚, 王小群. 循环肿瘤细胞预测晚期胃肠癌患者化疗药物敏感性的研究[J]. 中华普通外科学文献(电子版), 2023, 17(06): 422-425.
[2] 莫波, 王佩, 王恒, 何志军, 梁俊, 郝志楠. 腹腔镜胃癌根治术与改良胃癌根治术治疗早期胃癌的疗效[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 644-647.
[3] 索郎多杰, 高红桥, 巴桑顿珠, 仁桑. 腹腔镜下不同术式治疗肝囊型包虫病的临床疗效分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 670-673.
[4] 唐浩, 梁平, 徐小江, 曾凯, 文拨辉. 三维重建指导下腹腔镜右半肝加尾状叶切除治疗Bismuth Ⅲa型肝门部胆管癌的临床研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 688-692.
[5] 汪毅, 许思哲, 任章霞. 胸乳入路腔镜单侧甲状腺叶切除术与开放手术对分化型甲状腺癌患者术后恢复的影响[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 542-545.
[6] 顾睿祈, 方洪生, 蔡国响. 循环肿瘤DNA检测在结直肠癌诊治中的应用与进展[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 453-459.
[7] 邰清亮, 施波, 侍新宇, 陈国梁, 陈俊杰, 武冠廷, 王索, 孙金兵, 顾闻, 叶建新, 何宋兵. 腹腔镜次全结肠切除术治疗顽固性慢传输型便秘的疗效分析[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 478-483.
[8] 刘卓, 段虎斌. 生物电相关疗法在神经损伤修复中的应用进展[J]. 中华神经创伤外科电子杂志, 2023, 09(05): 257-260.
[9] 姜里蛟, 张峰, 周玉萍. 多学科诊疗模式救治老年急性非静脉曲张性上消化道大出血患者的临床观察[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 520-524.
[10] 梁文龙, 曹杰, 黄庆, 林泳, 黄红丽, 杨平, 李冠炜, 胡鹤. 信迪利单抗联合瑞戈非尼治疗晚期结直肠癌的疗效与安全性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 409-413.
[11] 高显奎, 赵太云, 陆兴俊, 张洪领, 房修罗, 闫碧春, 王胤, 王永翠, 刘苗苗, 冉若男. 内镜电凝止血与组织胶注射治疗上消化道溃疡伴出血的疗效观察[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 452-455.
[12] 张景旭, 李德舫, 由上可, 张玉田. 贝伐珠单抗与安罗替尼联合奥沙利铂治疗晚期直肠癌的临床疗效[J]. 中华消化病与影像杂志(电子版), 2023, 13(05): 289-293.
[13] 杨镠, 秦岚群, 耿茜, 李栋庆, 戚春建, 蒋华. 可溶性免疫检查点对胃癌患者免疫治疗疗效和预后的预测价值[J]. 中华消化病与影像杂志(电子版), 2023, 13(05): 305-311.
[14] 盛静, 梅勇, 夏佩, 王晓林. 乌苯美司联合伊立替康二线治疗晚期胃癌的临床研究[J]. 中华消化病与影像杂志(电子版), 2023, 13(05): 317-321.
[15] 李莹倩, 李华山. 基于真实世界的完全性直肠脱垂治疗方式评价[J]. 中华临床医师杂志(电子版), 2023, 17(06): 700-705.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号